ICER opens nominations for new members of its voting panels

2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

The real worth of cancer drugs

1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe ...

Read more →

Will COVID-19 vaccines be cost effective—and does it matter?

26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...

Read more →

Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic

19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...

Read more →

A health opportunity cost threshold for cost effectiveness analysis in the United State

3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...

Read more →

Efficiency ratio and rocketing drug prices: old concerns and new possibilities

23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...

Read more →

FDA announces all time low rates for FY2021 priority review vouchers

5 October 2020 - The US FDA has announced historic low rates for the fiscal year 2021 fees to use ...

Read more →

De-adopting low value care: evidence, eminence and economics

2 October 2020 - An often cited shortcoming of the US health care system is the slow pace with which ...

Read more →

Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?

10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets.  ...

Read more →

How can cancer drug prices better match their benefits? Germany offers a cost-saving model

10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...

Read more →

The case for using novel value elements when assessing COVID-19 vaccines and therapeutics

23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...

Read more →

ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence

19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...

Read more →

Trump administration seeks to encourage ‘value-based’ drug pricing deals with new proposal

17 June 2020 - The Trump administration wants to revamp certain Medicaid rules about drug prices in hopes of encouraging ...

Read more →

COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’

15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...

Read more →

Paying for value from costly medical technologies: a framework for applying value-based payment reforms

2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...

Read more →